A Major Cochrane Review Casts Doubt on the Efficacy and Safety of Amyloid-Targeting Alzheimer’s Drugs
A comprehensive analysis of 17 clinical trials involving over 20,000 participants has concluded that drugs designed to target amyloid beta proteins in the brain are unlikely to offer significant clinical…
The Promise and Peril of Anti-Amyloid Drugs for Alzheimer’s Disease: A Landmark Review Casts Doubt on Clinical Efficacy and Highlights Safety Concerns
A comprehensive and influential Cochrane review has delivered a significant blow to the long-held therapeutic strategy targeting amyloid beta proteins in the brain for Alzheimer’s disease, concluding that these drugs…








